Table 4

Effect of l-NAME and saline on airway responsiveness to histamine and AMP in each study phase

Patient no.		Phase 1: log PC₂₀		Patient no.		Phase 2: log PC₂₀
		Histamine						AMP		Histamine		AMP
		Saline	l-NAME 54 mg					Saline	l-NAME 54 mg	Saline	l-NAME 170 mg	Saline	l-NAME 170 mg
1^4-150	0.24	−0.49		1.65	2.15	1^4-150	0.24	−0.19		1.75	1.50
2^4-150	0.39	0.22		1.95	1.47	2^4-150	0.46	0.21		0.99	0.42
3^4-150	−0.09	0.63		0.69	1.20	3^4-150	−0.11	−0.50		1.03	0.87
4^4-150	−0.06	0.06		1.93	2.44	4^4-150	0.42	0.31		—	—
5^4-150	0.01	−0.82		1.22	1.24	5^4-150	0.22	−0.35		—	—
6	−0.11	−0.77		0.55	0.27	6	0.61	0.16		2.02	2.08
7	−0.22	−0.27		1.41	1.54	7	−0.15	−0.93		0.74	0.33
8	−0.78	−0.37		0.25	0.46	8	0.00	−0.16		1.29	0.89
9	−0.05	−0.34		1.47	0.98	9	0.30	−0.09		1.53	0.95
10^4-150	0.36	0.11				10^4-150	0.61	0.22		1.07	1.00
11^4-150	−0.84	−0.17				11^4-150	0.10	−0.12		2.24	2.05
12^4-150	0.45	0.02				12^4-150	0.29	0.43		1.70	1.07
13	0.09	−0.22				13				0.87	0.62
14	−0.53	−0.54
15	−0.24	−0.50
Mean	−0.09	−0.23		1.24	1.31		0.25	−0.08^4-151		1.39	1.07^4-151
95% CI	−0.31 to 0.12	−0.45 to −0.02		0.77 to 1.70	0.76 to 1.80		0.09 to 0.41	−0.33 to 0.16		1.05 to 1.72	0.68 to 1.46